Overexpression of cyclin A overrides the effect of p53 alterations in breast cancer patients with long follow-up time

Breast Cancer Research and Treatment

Volumn 80, Issue 2, 2003, Pages 199-206

  Bukholm, Ida R K ^a   Husdal, Anne ^a,b   Nesland, Jahn M ^b   Langerød, Anita ^c   Bukholm, Geir ^a,b  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c NONE

Author keywords

Breast carcinomas; Cyclin A; Histology grade; Immunohistochemistry; TP53

Indexed keywords

CYCLIN A; DNA; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GRADING; CELL CYCLE; DNA DAMAGE; DNA SEQUENCE; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; TUMOR CELL; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COHORT STUDIES; CYCLIN A; DNA PRIMERS; FEMALE; FOLLOW-UP STUDIES; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NORWAY; POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0038675073     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024527220362     Document Type: Article

References (30)

1. Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akselsen LA, Borresrn-Dale AL: Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 61: 2505-2512, 2001
2. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer I 85: 200-206, 1993
3. Andersen TI, Borresen AL: Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas. Advantages of using constant denaturant gel electrophoresis in mutation detection. Diagn Mol Pathol 4: 203-211, 1995
4. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L: Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1: 1029-1034, 1995
5. Gasparini G, Toi M, Verderio P, Ranieri G, Dante S, Bonoldi E, Boracchi P, Fanelli M, Tominaga T: Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients. Int J Oncol 12: 1117-1125, 1998
6. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993
7. Hsieh JK, Yap D, O'Connor DJ, Fogal V, Fallis L, Chan F, Zhong S, Lu X: Novel function of the cyclin A binding site of E2F in regulating p53-induced apoptosis in response to DNA damage. Mol Cell Biol 22: 78-93, 2002
8. Rosenblatt J, Gu Y, Morgan DO: Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A. P Natl Acad Sci USA 89: 2824-2828, 1992
9. Walker DH, Maller JL: Role for cyclin A in the dependence of mitosis on completion of DNA replication. Nature 354: 314-317, 1991
10. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G: Cyclin A is required at two points in the human cell cycle. EMBO J 11: 961-971, 1992
11. Faha B, Ewen ME, Tsai LH, Livingston DM, Harlow E: Interaction between human cyclin A and adenovirus E1A-associated p107 protein. Science 255: 87-90, 1992
12. Bandara LR, Adamczewski JP, Hunt T, La Thangue NB: Cyclin A and the retinoblastoma gene product complex with a common transcription factor. Nature 352: 249-251, 1991
13. Mudryj M, Devoto SH, Hiebert SW, Hunter T, Pines J, Nevins JR: Cell cycle regulation of the E2F transcription factor involves an interaction with cyclin A. Cell 65: 1243-1253, 1991
14. Volm M, Koomagi R, Mattern J, Stammler G: Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. Brit J Cancer 75: 1774-1778, 1997
15. Chao Y, Shih YL, Chiu JH, Chau GY, Lui WY, Yang WK, Lee SD, Huang TS: Overexpression of cyclin A but not Skp 2 correlates with the tumor relapse of human hepatocellular carcinoma. Cancer Res 58: 985-990, 1998
16. Handa K, Yamakawa M, Takeda H, Kimura S, Takahashi T: Expression of cell cycle markers in colorectal carcinoma: superiority of cyclin A as an indicator of poor prognosis. Int J Cancer 84: 225-233, 1999
17. Aaltomaa S, Lipponen P, Ala-Opas M, Eskelinen M, Syrjanen K, Kosma VM: Expression of cyclins A and D and p21 (waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival. Brit J Cancer 80: 2001-2007, 1999
18. Florenes VA, Maelandsmo GM, Faye R, Nesland JM, Holm R: Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome. J Pathol 195: 530-536, 2001
19. Michalides R, van Tinteren H, Balkenende A, Vermorken JB, Benraadt J, Huldij J, van Diest P: Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Brit J Cancer 86: 402-408, 2002
20. Bukholm IR, Bukholm G, Nesland JM: Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas. Int J Cancer 93: 283-287, 2001
21. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991
22. Bukholm IK, Nesland JM, Karesen R, Jacobsen U, Borresen AL: Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas. J Pathol 181: 140-145, 1997
23. Guldberg P, Nedergaard T, Nielsen HJ, Olsen AC, Ahrenkiel V, Zeuthen J: Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer. Hum Mutat 9: 348-355, 1997
24. Borresen AL, Hovig E, Smith-Sorensen B, Malkin D, Lystad S, Andersen TI, Nesland JM, Isselbacher KJ, Friend SH: Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. P Natl Acad Sci USA 88: 8405-8409, 1991
25. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849-852, 1993
26. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994
27. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993
28. Fan S, el-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Forance AJ, Magrath I, Kohn KW, O'Conner PM: p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 54: 5824-5830, 1994
29. Archer SG, Eliopoulos A, Spandidos D, Barnes D, Ellis IO, Blamey RW, Nicholson RI, Robertson JF: Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Brit J Cancer 72: 1259-1266, 1995
30. Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC, Pugh R, Ciocco D, Ravdin P, O'Sullivan J, Rivkin S, Martino S, Osborne CK: bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. J Clin Oncol 15: 1916-1922, 1997